Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 10, 2005, Pages 3855-3858

  Strøm, Charlotte ^a   Sander, Birgit ^a   Klemp, Kristian ^a   Aiello, Lloyd Paul ^b,c   Lund Andersen, Henrik ^a   Larsen, Michael ^a,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; ENZYME INHIBITOR; GLYCOSYLATED HEMOGLOBIN; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VISUAL ACUITY; BLOOD PRESSURE; CAPILLARY PERMEABILITY; DIABETIC RETINOPATHY; DRUG ANTAGONISM; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RETINA; RETINA BLOOD VESSEL; RETINA MACULA CYSTOID EDEMA;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD PRESSURE; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDOLES; MACULAR EDEMA, CYSTOID; MALE; MALEIMIDES; MIDDLE AGED; PROTEIN KINASE C; RETINA; RETINAL VESSELS;

EID: 32944465911     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0096     Document Type: Article

References (21)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng l J Med. 1993;329:977-986.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
3. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985;103:1796-1806.
5. Aiello LP: The potential role of PKC beta in diabetic retinopathy ad macular edema. Surv Ophthalmol. 2002;47(suppl 2):S263-S269.
6. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
7. Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complications of diabetes. Vitam Horm. 2000;60:149-193.
8. Sander B, Larsen M, Moldow B, Lund-Andersen H. Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. Invest Ophthalmol Vis Sci. 2001;42:433-438.
9. Sander B, Larsen M, Engler C, et al. Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy. Br J Ophthalmol. 2002;86:316-320.
10. Moldow B, Sander B, Larsen M, Lu, Lund-Andersen H. Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB. Invest Ophthalmol Vis Sci. 1999;40:1770-1775.
11. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification-ETDRS report number 10. Ophthalmology 1991;98(suppl 5):786-806.
12. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-1474.
13. Dalgaard P, Larsen M. Fitting numerical solutions of differential equations to experimental data: a case study and some general remarks. Biometrics. 1990;46:1097-1109.
14. Larsen M, Lund-Andersen H. Lens fluorometry: light-attenuation effects and estimation of total lens transmittance. Graefes Arch Clin Exp Ophthalmol. 1991;229:363-370.
15. Larsen M, Dalgaard P, Lund-Andersen H. Differential spectrofluorometry in the human vitreous: blood-retina barrier permeability to fluorescein and fluorescein glucuronide. Graefes Arch Clin Exp Ophthalmol. 1991;229:350-357.
16. Larsen M, Dalgaard P, Lund-Andersen H. Determination of spatial coordinates in ocular fluorometry. Graefes Arch Clin Exp Ophthalmol. 1991;229:358-362.
17. Lund-Andersen H, Krogsaa B, la Cour M, Larsen J. Quantitative vitreous fluorophotometry applying a mathematical model of the eye. Invest Ophthalmol Vis Sci. 1985;26:698-710.
18. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998;39:171-179.
19. Jirousek MR, Koya D, Takagi C, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272:728-731.
20. Krogsaa B, Lund-Andersen H, Mehlsen J, Sestoft L, Larsen J. The blood-retinal barrier permeability in diabetic patients. Acta Ophthalmol (Copenh). 1981;59:689-694.
21. Larsen M, Hommel E, Parving H-H, Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol. 1990;228:505-509.